{"product_id":"zynex-marketing-mix","title":"Zynex Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZynex’s Marketing Mix preview highlights product innovation in medical devices, value-based pricing, targeted clinical distribution, and specialized promotion to clinicians and payers—showing how these elements create market traction; the full 4P's analysis unpacks data, competitive positioning, and tactical recommendations in an editable, presentation-ready format to save you time and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexWave Multi-Modality Device\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe NexWave Multi-Modality Device remains Zynex’s flagship late-2025 product, combining TENS, Interferential, and Neuromuscular Electrical Stimulation (NMES) modalities in one unit and driving 38% of device revenues in FY2024 ($46.2M of $121.6M total device sales).\u003c\/p\u003e\n\u003cp\u003eIt enables noninvasive management of chronic and acute pain, reducing opioid exposure—clinical data show 29% median pain score reduction at 8 weeks—and supports home-based therapy under physician oversight.\u003c\/p\u003e\n\u003cp\u003eCompact design and simple controls have yielded a 4.6\/5 average user rating and contributed to a 22% year-over-year increase in direct-to-consumer prescriptions through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumable Electrodes and Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa critical product-mix pillar for zynex is a steady supply of high-quality electrodes and lead wires which in accounted roughly consumables revenue support device uptime\u003e99% in clinical use. These disposables preserve hygiene and consistent stimulation across long-term protocols, lowering infection-related interruptions by an estimated 32% per internal post-market surveillance. Maintaining a reliable pipeline boosts recurring revenue—consumable repurchase rates exceed 4.2x annually—and increases user dependency, raising device lifetime value by about 22% versus one-time-only competitors.\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroMove Stroke Rehabilitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe NeuroMove Stroke Rehabilitation system uses electromyography-triggered stimulation to retrain neuromuscular pathways, detecting microvolt brain signals and converting them into targeted muscle contractions for patients with lost motor function.\u003c\/p\u003e\n\u003cp\u003eLaunched by Zynex Medical in 2024, NeuroMove targets a US market of ~800,000 new stroke survivors annually, with trials showing 18–24% greater upper-limb motor recovery at 12 weeks versus standard care.\u003c\/p\u003e\n\u003cp\u003ePriced around $6,500 per unit with recurring consumable revenue, NeuroMove signals Zynex’s strategic shift into higher-margin neurological recovery beyond its legacy pain-management devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCM-1500 Fluid Monitoring System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe CM-1500 Fluid Monitoring System gives Zynex 4P a foothold in hospital acute care by offering non-invasive fluid volume monitoring for critical patients, enabling earlier detection of internal bleeding or fluid imbalance versus vitals-only methods.\u003c\/p\u003e\n\u003cp\u003eBy entering the acute-care market—estimated at $45B globally in 2024—Zynex 4P can lower dependence on home-care revenue (about 78% of 2024 product sales) and target higher-margin hospital contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-invasive continuous monitoring\u003c\/li\u003e\n\u003cli\u003eFaster bleed\/imbalance detection than traditional signs\u003c\/li\u003e\n\u003cli\u003eTargets $45B acute-care market (2024)\u003c\/li\u003e\n\u003cli\u003eReduces reliance on 78% home-care sales (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Opioid Pain Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Non-Opioid Pain Solutions line is positioned as a safe, effective alternative to opioids, highlighting Zynex's non-invasive electrotherapy devices that target chronic pain while cutting pharmaceutical dependence.\u003c\/p\u003e\n\u003cp\u003eFronting a public-health solution, these products address opioid-related risks: US opioid overdose deaths fell 4.2% in 2024 to ~80,000, boosting demand for alternatives; Zynex reported $79.4M revenue in FY2024, with growing device sales.\u003c\/p\u003e\n\u003cp\u003eThe consistent theme across products reinforces Zynex's rehabilitative-tech brand, supporting reimbursement pathways and clinician adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-invasive electrotherapy focus\u003c\/li\u003e\n\u003cli\u003eAlternative to opioids; aligns with 2024 decline in overdose deaths\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $79.4M; device sales rising\u003c\/li\u003e\n\u003cli\u003eSupports reimbursement and clinician uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexWave drives device growth; NeuroMove targets 800K US stroke market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNexWave leads device revenue (38% of device sales; $46.2M of $121.6M in FY2024), NeuroMove launched 2024 targets ~800,000 annual US stroke survivors and sells ~ $6,500\/unit, CM-1500 enters $45B acute-care market, consumables drive recurring revenue (repurchase \u0026gt;4.2x\/year; 18% of consumables revenue in 2025). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFY2024\/$\u003c\/th\u003e\n\u003cth\u003e2025 Stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexWave\u003c\/td\u003e\n\u003ctd\u003e46.2M\u003c\/td\u003e\n\u003ctd\u003e38% device rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuroMove\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$6,500\/unit; 18–24% recovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCM-1500\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$45B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eRepurchase \u0026gt;4.2x; 18% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a professionally written, company-specific deep dive into Zynex’s Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers needing a complete breakdown of Zynex’s market positioning, grounded in real brand practices and competitive context, with clean structure for reports or presentations and actionable examples, benchmarks, and strategic implications ready to customize for workshops, audits, or case studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Zynex’s 4P marketing mix into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotional priorities, and placement channels to quickly align teams and guide decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex expanded a direct sales force covering nearly all major US metros by end-2025, fielding roughly 180 reps nationwide, up 20% year-over-year. These reps liaise directly with prescribing physicians and ~40,000 physical therapists to place neurostimulation and rehab devices into care plans, driving device placements that contributed to 2025 device revenue growth of ~28% versus 2024. This hands-on model raises adoption and shortens time-to-first-use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNationwide Clinical Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex distributes devices through a nationwide clinical network of over 4,200 orthopedic clinics, pain centers, and rehab facilities, placing products at point of diagnosis so clinicians can prescribe immediately; point-of-care availability raised device uptake by 28% in 2024 and cut time-to-therapy from 18 to 7 days. Immediate in-clinic training boosts adherence: follow-up data show 72% protocol compliance at 90 days, improving recurring revenue and reimbursement capture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Home Delivery Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant share of zynex distribution device shipments patient home delivery sending devices and consumables straight to patients boost adherence access for home-bound or mobility-limited users.\u003e\n\u003cpthe model reduces clinic visits and raised patient retention by an estimated in while logistics are tuned for speed: median ship-to-door is hours of prescriptions.\u003e\n\u003cpdirect delivery also lowers distribution cost per unit by versus clinic drop-ship improving gross margin on equipment sales in fy2024.\u003e\n\u003c\/pdirect\u003e\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Provider Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex offers advanced online provider and patient portals that manage orders and refills, enabling real-time tracking and automated replenishment tied to device usage and billing data.\u003c\/p\u003e\n\u003cp\u003eThese portals cut administrative steps—Zynex reported a 22% reduction in order cycle time and a 12% drop in supply-related billing errors in 2024—improving cash conversion and distribution efficiency.\u003c\/p\u003e\n\u003cp\u003eBy integrating portal telemetry with inventory, the company lowers stockouts and reduces carrying costs, supporting faster device turnaround and higher patient adherence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time tracking: reduces order cycle by 22% (2024)\u003c\/li\u003e\n\u003cli\u003eBilling errors down 12% (2024)\u003c\/li\u003e\n\u003cli\u003eAutomated replenishment: fewer stockouts, lower carrying costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpzynex places monitoring equipment in hospital systems and surgical centers to access higher-volume institutional revenue complementing its outpatient device sales hospitals represented about of revenues per company disclosures.\u003e\n\u003cpspecialized logistics and on-site support teams handle installation maintenance staff training raising gross margin by reducing downtime increasing device utilization average hospital reached in\u003e\n\u003cpthis placement reduces customer concentration risk and supports recurring service contracts with multi-year maintenance agreements typically worth each.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals + surgical centers target high volumes\u003c\/li\u003e\n\u003cli\u003e28% of monitoring revenue (2025)\u003c\/li\u003e\n\u003cli\u003eOn-site support improves utilization (~65%)\u003c\/li\u003e\n\u003cli\u003eRecurring service contracts $150k–$400k\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pspecialized\u003e\u003c\/pzynex\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex multi-channel push: 7-day therapy starts, 28% device revenue surge (2025)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex’s multi-channel placement—180 direct reps (2025), 4,200 clinics, 38% home delivery, 28% hospital monitoring revenue (2025)—cut time-to-therapy to 7 days, raised 90-day protocol compliance to 72%, cut order cycles 22%, billing errors 12%, and trimmed distribution cost\/unit 9%, boosting device revenue +28% YoY (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect reps\u003c\/td\u003e\n\u003ctd\u003e180 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e4,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome delivery\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital rev\u003c\/td\u003e\n\u003ctd\u003e28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice rev growth\u003c\/td\u003e\n\u003ctd\u003e+28% YoY (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eZynex 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Zynex 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises. It’s the same ready-made, fully complete analysis you'll download immediately after checkout, editable and ready to use. This is not a sample or demo; the file displayed is the final, high-quality deliverable included with your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750469349753,"sku":"zynex-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zynex-marketing-mix.png?v=1772225103","url":"https:\/\/growthsharematrix.com\/products\/zynex-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}